Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Novo Nordisk’s Diabetes Franchise Bears The Weight Of Disappointing Obesity Sales
As Manufacturing Issues Continue
Feb 02 2022
•
By
Ayisha Sharma
Novo Is Known For Its Diabetes Franchise But Wegovy Is Touted As A Blockbuster Obesity Drug. • Source: Alamy
More from Earnings
More from Business